PERSPECTA

News from every angle

← Back to headlines

Ardelyx Reaffirms 2026 Guidance, Targets $1B for IBSRELA by 2029

Pharmaceutical company Ardelyx has reiterated its financial guidance for 2026 and set a target of $1 billion in sales for its drug IBSRELA by 2029. The company is also progressing with Phase III enrollment for ACCEL CIC by year-end.

1 May, 02:02 — 1 May, 02:02
PostShare

Sources

Showing 1 of 1 sources
seeking-alphaMixed1h ago

Ardelyx reiterates 2026 guidance as IBSRELA targets $1B in 2029 while advancing ACCEL CIC Phase III enrollment by year-end

Read full article →

Related Stories

Filipinos' Top Worries for 2026 Revealed in Octa Survey

just now

Editorial Highlights Rising Youth Crime and Mental Health Concerns

just now

Dangerous Heat Index Levels Persist Across Philippines into Early May

just now

RSV Vaccine Reoffered to Pregnant Women After Drop in Infant Admissions

50m ago